Mark Currier, Author at CLD

Solutions e-learning

January 21, 2020

Marketplace Manager: Competitor Package Insert (PI) Tool

The Marketplace Manager provides sales trainers the ability to present readily accessible competitor information to…

Mark Currier

Love0

Learning Science

August 20, 2019

Should Reps Read or Listen?: New Study Sheds Light On Audiobooks

In her recent article Sarah Knapton, science editor for the Telegraph, breaks down the latest…

Mark Currier

Love0

Solutions e-learning

July 29, 2019

Real-Time Pull Through

Most learners really don't mind knowledge checks until they start getting questions wrong. CLD creates…

Mark Currier

Love0

Tools for Trainers

July 8, 2019

How Life Science Sales Trainers Can Use Google’s Data GIF Maker

Google Data GIF Maker is a free tool that makes data visualization and data comparison…

Mark Currier

Love0

Solutions

June 13, 2019

The iKnow™ Oncology Fundamentals series

Forty years of providing cutting-edge oncology training must mean you know a thing or two.…

Mark Currier

Love0

Trends

June 25, 2019

Cell Phone Breaks and 20 Minute Meetings: An NFL Coach is Doing it. Should Pharma Sales Trainers follow Suit?

Attention spans are shrinking, and the average person checks their phone 47 times day. If…

Mark Currier

Love0

Trends

February 13, 2019

Big Pharma will be forced to reevaluate their business model

https://www.pharmalive.com/annual-report-2019-top-10-pipelines-to-watch/

Mark Currier

Love0

Featured

January 15, 2019

How This Billion-Dollar CEO Built a Winning Team from Inc. Video

Sprout Pharmaceuticals', Cindy Eckert, discusses how she fired her top salesperson. Her Inc. Video interview provides…

Mark Currier

Love0

Sales Training Trends

October 11, 2017

What you need to know: The evolving pharma sales force

What you need to know: The evolving pharma sales force BioPharmaDive article written by Lisa LaMotta…

Mark Currier

Love0

The average investment for a first indication launch was $13 million, with an average maximum spend of $20 million across the 12 pharma companies surveyed, which included Pfizer, Amgen, Bayer, Novartis and Eli Lilly.

Best Practices / Beth Snyder Bulik

Mark Currier

The average investment for a first indication launch was $13 million, with an average maximum spend of $20 million across the 12 pharma companies surveyed, which included Pfizer, Amgen, Bayer, Novartis and Eli Lilly.

Categories